100 related articles for article (PubMed ID: 17924607)
1. Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity.
Vander Cruyssen B; Miltenburg AM; Van den Bosch F; Houbiers JG; Wittoek R; Boots AM; De Keyser F
J Rheumatol; 2007 Oct; 34(10):1992-6. PubMed ID: 17924607
[TBL] [Abstract][Full Text] [Related]
2. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
4. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.
Lundström E; Källberg H; Smolnikova M; Ding B; Rönnelid J; Alfredsson L; Klareskog L; Padyukov L
Arthritis Rheum; 2009 Apr; 60(4):924-30. PubMed ID: 19333936
[TBL] [Abstract][Full Text] [Related]
6. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
7. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
[TBL] [Abstract][Full Text] [Related]
8. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Feitsma AL; Toes RE; Begovich AB; Chokkalingam AP; de Vries RR; Huizinga TW; van der Helm-van Mil AH
Rheumatology (Oxford); 2007 Jul; 46(7):1092-5. PubMed ID: 17341507
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
10. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.
Bos WH; Ursum J; de Vries N; Bartelds GM; Wolbink GJ; Nurmohamed MT; van der Horst-Bruinsma IE; van de Stadt RJ; Crusius JB; Tak PP; Dijkmans BA; van Schaardenburg D
Ann Rheum Dis; 2008 Sep; 67(9):1347-50. PubMed ID: 18388157
[TBL] [Abstract][Full Text] [Related]
11. The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
Saruhan-Direskeneli G; Inanc M; Fresko I; Akkoc N; Dalkilic E; Erken E; Karaaslan Y; Kinikli G; Oksel F; Pay S; Yucel E; Yentür SP; Duymaz-Tozkir J; Yilmaz V; Inanc N; Yazici H; Konice M; Direskeneli H
Rheumatology (Oxford); 2007 Dec; 46(12):1842-4. PubMed ID: 18032542
[TBL] [Abstract][Full Text] [Related]
12. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.
van der Woude D; Houwing-Duistermaat JJ; Toes RE; Huizinga TW; Thomson W; Worthington J; van der Helm-van Mil AH; de Vries RR
Arthritis Rheum; 2009 Apr; 60(4):916-23. PubMed ID: 19333951
[TBL] [Abstract][Full Text] [Related]
13. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.
Verpoort KN; Cheung K; Ioan-Facsinay A; van der Helm-van Mil AH; de Vries-Bouwstra JK; Allaart CF; Drijfhout JW; de Vries RR; Breedveld FC; Huizinga TW; Pruijn GJ; Toes RE
Arthritis Rheum; 2007 Dec; 56(12):3949-52. PubMed ID: 18050209
[TBL] [Abstract][Full Text] [Related]
14. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
[TBL] [Abstract][Full Text] [Related]
15. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.
Hoppe B; Häupl T; Egerer K; Gruber R; Kiesewetter H; Salama A; Burmester GR; Dörner T
Ann Rheum Dis; 2009 Jun; 68(6):898-903. PubMed ID: 18633125
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
Nikolaisen C; Rekvig OP; Nossent HC
Scand J Rheumatol; 2005; 34(4):269-76. PubMed ID: 16195159
[TBL] [Abstract][Full Text] [Related]
17. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.
Kapitány A; Szabó Z; Lakos G; Aleksza M; Végvári A; Soós L; Karányi Z; Sipka S; Szegedi G; Szekanecz Z
Isr Med Assoc J; 2008 Jan; 10(1):32-6. PubMed ID: 18300568
[TBL] [Abstract][Full Text] [Related]
18. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
[TBL] [Abstract][Full Text] [Related]
19. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
[TBL] [Abstract][Full Text] [Related]
20. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X; Jia R; Zhao J; Li Z
J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
